Double modulation of 5-fluorouracil by methotrexate and high-dose K- leucovorin in advanced colorectal cancer

A. O. Romero, J. E. Perez, M. A. Cuevas, J. A. Lacava, C. L. Sabatini, M. E. Dominguez, R. Rodriguez, M. R. Barbieri, E. H. Ortiz, M. A. Salvadori, L. A. Romero Acuña, J. M. Romero Acuña, M. J. Langhi, S. Amato, M. R. Machiavelli, B. A. Leone, C. T. Vallejo, V. Lorusso, M. DeLena

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A phase II trial was performed to evaluate the efficacy and toxicity of a double modulation of 5-fluorouracil (5-FU) by methotrexate (MTX) and L- leucovorin (L-LV) in patients with advanced recurrent (inoperable) or metastatic colorectal carcinoma (ACC). Between July 1993 and October 1995, 41 patients with ACC received a regimen that consisted of MTX 150 mg/m2 i.v., infused over a 20-minute period at hour 0, followed 19 hours later by L-LV 250 mg/m2 in a 2-hour i.v. infusion. 5-FU, 900 mg/m2, was administered by i.v. push injection at hour 20. Beginning 24 hours after MTX administration, all patients received four doses of L-LV, 15 mg/m2 i.m., every 6 hours. Cycles were repeated every 15 days. Two patients were not assessable for response. Objective regression was observed in 11 of 39 (28%) patients, [95% confidence interval (CI), 14-42%]. One (2%) patient achieved complete response (CR) and 10 (26%) partial response (PR). No change was recorded in 15 (39%) patients and progressive disease was noted in 13 (33%) patients. The median time to treatment failure was 6 months and the median survival time was 10 months. Toxicity was within acceptable limits, but one therapy- related death due to severe leukopenia was observed. The dose-limiting toxicity was mucositis. Eight episodes of grade 3 or 4 stomatitis were observed, and were responsible for dosage modifications of MTX and 5-FU. In conclusion, further in experimental and clinical studies are clearly necessary in order to design the best modulatory strategy of 5-FU.

Original languageEnglish
Pages (from-to)94-98
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume21
Issue number1
DOIs
Publication statusPublished - Feb 1998

Fingerprint

Leucovorin
Methotrexate
Fluorouracil
Colorectal Neoplasms
Stomatitis
Mucositis
Leukopenia
Treatment Failure
Confidence Intervals
Injections
Survival

Keywords

  • 5-FU
  • Biomodulation
  • Colorectal cancer
  • L-leucovorin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Double modulation of 5-fluorouracil by methotrexate and high-dose K- leucovorin in advanced colorectal cancer. / Romero, A. O.; Perez, J. E.; Cuevas, M. A.; Lacava, J. A.; Sabatini, C. L.; Dominguez, M. E.; Rodriguez, R.; Barbieri, M. R.; Ortiz, E. H.; Salvadori, M. A.; Romero Acuña, L. A.; Romero Acuña, J. M.; Langhi, M. J.; Amato, S.; Machiavelli, M. R.; Leone, B. A.; Vallejo, C. T.; Lorusso, V.; DeLena, M.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 21, No. 1, 02.1998, p. 94-98.

Research output: Contribution to journalArticle

Romero, AO, Perez, JE, Cuevas, MA, Lacava, JA, Sabatini, CL, Dominguez, ME, Rodriguez, R, Barbieri, MR, Ortiz, EH, Salvadori, MA, Romero Acuña, LA, Romero Acuña, JM, Langhi, MJ, Amato, S, Machiavelli, MR, Leone, BA, Vallejo, CT, Lorusso, V & DeLena, M 1998, 'Double modulation of 5-fluorouracil by methotrexate and high-dose K- leucovorin in advanced colorectal cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 21, no. 1, pp. 94-98. https://doi.org/10.1097/00000421-199802000-00022
Romero, A. O. ; Perez, J. E. ; Cuevas, M. A. ; Lacava, J. A. ; Sabatini, C. L. ; Dominguez, M. E. ; Rodriguez, R. ; Barbieri, M. R. ; Ortiz, E. H. ; Salvadori, M. A. ; Romero Acuña, L. A. ; Romero Acuña, J. M. ; Langhi, M. J. ; Amato, S. ; Machiavelli, M. R. ; Leone, B. A. ; Vallejo, C. T. ; Lorusso, V. ; DeLena, M. / Double modulation of 5-fluorouracil by methotrexate and high-dose K- leucovorin in advanced colorectal cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1998 ; Vol. 21, No. 1. pp. 94-98.
@article{dea2d4ea81264bef8ef8d9dc023bdfe1,
title = "Double modulation of 5-fluorouracil by methotrexate and high-dose K- leucovorin in advanced colorectal cancer",
abstract = "A phase II trial was performed to evaluate the efficacy and toxicity of a double modulation of 5-fluorouracil (5-FU) by methotrexate (MTX) and L- leucovorin (L-LV) in patients with advanced recurrent (inoperable) or metastatic colorectal carcinoma (ACC). Between July 1993 and October 1995, 41 patients with ACC received a regimen that consisted of MTX 150 mg/m2 i.v., infused over a 20-minute period at hour 0, followed 19 hours later by L-LV 250 mg/m2 in a 2-hour i.v. infusion. 5-FU, 900 mg/m2, was administered by i.v. push injection at hour 20. Beginning 24 hours after MTX administration, all patients received four doses of L-LV, 15 mg/m2 i.m., every 6 hours. Cycles were repeated every 15 days. Two patients were not assessable for response. Objective regression was observed in 11 of 39 (28{\%}) patients, [95{\%} confidence interval (CI), 14-42{\%}]. One (2{\%}) patient achieved complete response (CR) and 10 (26{\%}) partial response (PR). No change was recorded in 15 (39{\%}) patients and progressive disease was noted in 13 (33{\%}) patients. The median time to treatment failure was 6 months and the median survival time was 10 months. Toxicity was within acceptable limits, but one therapy- related death due to severe leukopenia was observed. The dose-limiting toxicity was mucositis. Eight episodes of grade 3 or 4 stomatitis were observed, and were responsible for dosage modifications of MTX and 5-FU. In conclusion, further in experimental and clinical studies are clearly necessary in order to design the best modulatory strategy of 5-FU.",
keywords = "5-FU, Biomodulation, Colorectal cancer, L-leucovorin",
author = "Romero, {A. O.} and Perez, {J. E.} and Cuevas, {M. A.} and Lacava, {J. A.} and Sabatini, {C. L.} and Dominguez, {M. E.} and R. Rodriguez and Barbieri, {M. R.} and Ortiz, {E. H.} and Salvadori, {M. A.} and {Romero Acu{\~n}a}, {L. A.} and {Romero Acu{\~n}a}, {J. M.} and Langhi, {M. J.} and S. Amato and Machiavelli, {M. R.} and Leone, {B. A.} and Vallejo, {C. T.} and V. Lorusso and M. DeLena",
year = "1998",
month = "2",
doi = "10.1097/00000421-199802000-00022",
language = "English",
volume = "21",
pages = "94--98",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Double modulation of 5-fluorouracil by methotrexate and high-dose K- leucovorin in advanced colorectal cancer

AU - Romero, A. O.

AU - Perez, J. E.

AU - Cuevas, M. A.

AU - Lacava, J. A.

AU - Sabatini, C. L.

AU - Dominguez, M. E.

AU - Rodriguez, R.

AU - Barbieri, M. R.

AU - Ortiz, E. H.

AU - Salvadori, M. A.

AU - Romero Acuña, L. A.

AU - Romero Acuña, J. M.

AU - Langhi, M. J.

AU - Amato, S.

AU - Machiavelli, M. R.

AU - Leone, B. A.

AU - Vallejo, C. T.

AU - Lorusso, V.

AU - DeLena, M.

PY - 1998/2

Y1 - 1998/2

N2 - A phase II trial was performed to evaluate the efficacy and toxicity of a double modulation of 5-fluorouracil (5-FU) by methotrexate (MTX) and L- leucovorin (L-LV) in patients with advanced recurrent (inoperable) or metastatic colorectal carcinoma (ACC). Between July 1993 and October 1995, 41 patients with ACC received a regimen that consisted of MTX 150 mg/m2 i.v., infused over a 20-minute period at hour 0, followed 19 hours later by L-LV 250 mg/m2 in a 2-hour i.v. infusion. 5-FU, 900 mg/m2, was administered by i.v. push injection at hour 20. Beginning 24 hours after MTX administration, all patients received four doses of L-LV, 15 mg/m2 i.m., every 6 hours. Cycles were repeated every 15 days. Two patients were not assessable for response. Objective regression was observed in 11 of 39 (28%) patients, [95% confidence interval (CI), 14-42%]. One (2%) patient achieved complete response (CR) and 10 (26%) partial response (PR). No change was recorded in 15 (39%) patients and progressive disease was noted in 13 (33%) patients. The median time to treatment failure was 6 months and the median survival time was 10 months. Toxicity was within acceptable limits, but one therapy- related death due to severe leukopenia was observed. The dose-limiting toxicity was mucositis. Eight episodes of grade 3 or 4 stomatitis were observed, and were responsible for dosage modifications of MTX and 5-FU. In conclusion, further in experimental and clinical studies are clearly necessary in order to design the best modulatory strategy of 5-FU.

AB - A phase II trial was performed to evaluate the efficacy and toxicity of a double modulation of 5-fluorouracil (5-FU) by methotrexate (MTX) and L- leucovorin (L-LV) in patients with advanced recurrent (inoperable) or metastatic colorectal carcinoma (ACC). Between July 1993 and October 1995, 41 patients with ACC received a regimen that consisted of MTX 150 mg/m2 i.v., infused over a 20-minute period at hour 0, followed 19 hours later by L-LV 250 mg/m2 in a 2-hour i.v. infusion. 5-FU, 900 mg/m2, was administered by i.v. push injection at hour 20. Beginning 24 hours after MTX administration, all patients received four doses of L-LV, 15 mg/m2 i.m., every 6 hours. Cycles were repeated every 15 days. Two patients were not assessable for response. Objective regression was observed in 11 of 39 (28%) patients, [95% confidence interval (CI), 14-42%]. One (2%) patient achieved complete response (CR) and 10 (26%) partial response (PR). No change was recorded in 15 (39%) patients and progressive disease was noted in 13 (33%) patients. The median time to treatment failure was 6 months and the median survival time was 10 months. Toxicity was within acceptable limits, but one therapy- related death due to severe leukopenia was observed. The dose-limiting toxicity was mucositis. Eight episodes of grade 3 or 4 stomatitis were observed, and were responsible for dosage modifications of MTX and 5-FU. In conclusion, further in experimental and clinical studies are clearly necessary in order to design the best modulatory strategy of 5-FU.

KW - 5-FU

KW - Biomodulation

KW - Colorectal cancer

KW - L-leucovorin

UR - http://www.scopus.com/inward/record.url?scp=0031891542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031891542&partnerID=8YFLogxK

U2 - 10.1097/00000421-199802000-00022

DO - 10.1097/00000421-199802000-00022

M3 - Article

C2 - 9499269

AN - SCOPUS:0031891542

VL - 21

SP - 94

EP - 98

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -